



## **Acarix welcomes Jeff Thomas as new Head of US Sales**

**Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announces the appointment of Jeff Thomas as the new Head of US Sales, effective June 1st, 2024. With over two decades of sales experience in the medical device and healthcare industries, Thomas brings outstanding expertise and leadership to his new role, setting the stage for exciting new developments at Acarix.**

Throughout his career, Thomas has consistently delivered exceptional results, both in Fortune 100 companies and start-ups. His deep understanding of market trends in the healthcare sector, particularly in cardiovascular therapy, positions him as a strategic asset for Acarix. Thomas' broad experience at Biotronik, Inc., St. Jude Medical, Guidant Corp (now Boston Scientific), and other leading MedTech companies highlights his exceptional performance, leadership, and commitment to improving patient outcomes.

"We are thrilled to welcome Jeff to our team," said Acarix President & CEO Aamir Mahmood. "His track record of success and deep understanding of the industry will play a pivotal role in driving our sales strategies and expanding our market presence in the United States."

Prior to joining Acarix, Thomas served as the Executive VP of Sales & Business Development at Vitalus Health, where he led all aspects of sales strategy, resulting in significant revenue growth and the expansion of the customer base. His achievements include developing and implementing revenue growth strategies, fostering a high-performance culture, and building key stakeholder relationships.

As the new Head of US Sales at Acarix, Thomas will lead the company's sales initiatives, drive revenue growth, and strengthen relationships with healthcare providers across the United States.

### **For more information contact:**

Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email [jennifer.anderson@acarix.com](mailto:jennifer.anderson@acarix.com)

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com)

27 May 2024 10:20:00 CEST



**Attachments**

[Acarix welcomes Jeff Thomas as new Head of US Sales](#)